Clinical trials: Insulin
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes
This study is conducted in Asia. The aim of this observational study is to compare the clinical safety profile and effectiveness of NovoMix® 30 and Levemir™ for the treatment of diabetes in the Philippines.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- SAFE (NCT00789711)
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Philippines
- Volunteers
- 3,131 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.
- Trial name
- NCT01464099
- Testing
- insulin aspart
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Healthy
Metabolic Effect of High-protein Meals in Men
The purpose of the clinical study is to investigate the effect of the protein quality of high-protein meal replacements on the management of post-prandial blood glucose in healthy men.
- Trial name
- OPTI-PROT (NCT00712010)
- Testing
- Whey protein native, Whey protein microgels, Hydrolyzed whey protein
- Where
- Switzerland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
- Trial name
- NCT07187479
- Testing
- Physiologic Insulin Resensitization (PIR)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Well Cell Global
Diabetes Mellitus, Type 1
Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.
The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.
- Trial name
- NCT03220425
- Testing
- Insulin detemir, NPH insulin
- Where
- 93 sites in Australia, Belgium and 8 more
- Volunteers
- 752 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
The trial is conducted in Asia. The aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in Taiwanese patients with type 2 diabetes failing on OAD with/without once-daily NPH Insulin treatment.
- Trial name
- NCT00521690
- Testing
- insulin detemir
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
Primary objectives : To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus…
- Trial name
- OSIRIS (NCT00174642)
- Testing
- Insulin Glargine, Insulin Glulisine, Metformin
- Where
- 18 sites in Belgium, France and 16 more
- Volunteers
- 811 people
- Sponsor
- Sanofi
Type1 Diabetes Mellitus
A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump
This is a single-centre, randomised, double-blind, three-period, complete cross-over trial comparing the pharmacokinetic and the pharmacodynamic properties of BioChaperone® insulin lispro and the two active comparators Fiasp® and…
- Trial name
- NCT03179332
- Testing
- BioChaperone® insulin lispro, Fiasp®, Novorapid®
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus
Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)
To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type…
- Trial name
- IDE2 (NCT03064906)
- Testing
- Insulet AP (artificial pancreas) System
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Insulet Corporation
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin.
- Trial name
- NCT02036515
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 464 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily…
- Trial name
- ADAPT (NCT00117780)
- Testing
- insulin detemir, insulin aspart
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT01572740
- Testing
- liraglutide, insulin
- Where
- 23 sites in Japan
- Volunteers
- 257 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes
This trial is conducted in South America. This trial aims for a comparison of the safety and efficacy of insulin NPH and a new insulin formulation on blood glucose control.
- Trial name
- NCT00660374
- Testing
- insulin NPH, EX1000
- Where
- Brazil
- Volunteers
- 402 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Glycemic Response in Adults with Diabetes
This will be a randomized crossover design with oral nutrition supplement interventions.
- Trial name
- NCT05026424
- Testing
- Balance oral nutritional drink - control, Balance oral nutritional drink - test
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Société des Produits Nestlé (SPN)
Type 1 Diabetes Mellitus (T1DM)
Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil
Multi-centre, open label, multiple ascending dose trial in patients with type 1 diabetes mellitus
- Trial name
- NCT04141423
- Testing
- Tregopil
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Biocon Limited
Diabetes Mellitus, Type 1
Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro
Primary Objective: To compare the immunogenicity of Gan \& Lee Insulin Lispro Injection and EU-authorized Humalog following treatment in adult subjects with T1DM Secondary Objectives: To evaluate the safety of Gan \& Lee Insulin…
- Trial name
- GENTL 1 (NCT04254380)
- Testing
- Gan & Lee Insulin Lispro Injection, Humalog
- Where
- 107 sites in United States, Czechia and 4 more
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus
This study is designed to explore the efficacy of ORMD-0801 compared to placebo on endogenous glucose production in subjects with type 2 diabetes (T2DM).
- Trial name
- NCT04564846
- Testing
- ORMD-0801
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Oramed, Ltd.
Diabetes, Diabetes Mellitus, Type 1
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
- Trial name
- NCT00071448
- Testing
- insulin human, insulin lispro, insulin aspart
- Where
- 76 sites in United States
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants
BC106 is a molecule that when injected with insulin lispro may change the speed of absorption of insulin lispro. The purpose of this study will be to evaluate the safety of BC106 insulin lispro and any side effects that might be…
- Trial name
- NCT01638325
- Testing
- Insulin Lispro, BC106 insulin lispro
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Adocia